Opioids Stuck In Pipeline Should Not Wait For REMS, National Pain Foundation Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Products can be folded into new class-wide risk management plan once it is developed, foundation tells FDA public meeting.
You may also be interested in...
Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins
Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins
Opioid REMS Pilot Program Urged At Public Meeting
FDA wrestles with balancing the urgency of patient safety with the desire for a well designed risk management program for pain products.